Cargando…

The prognostic impact of lung adenocarcinoma predominance classification relating to pathological factors in lobectomy, the Japanese Joint Committee of Lung Cancer Registry Database in 2010

OBJECTIVE: We studied the prognosis and clinicopathological background of lung adenocarcinoma predominance among patients who underwent lobectomy using data from the Japanese Joint Committee of Lung Cancer Registry. METHODS: Two thousand eight hundred sixty-three cases were extracted. Recurrence fre...

Descripción completa

Detalles Bibliográficos
Autores principales: Ito, Hiroyuki, Date, Hiroshi, Shintani, Yasushi, Miyaoka, Etsuo, Nakanishi, Ryoichi, Kadokura, Mitsutaka, Endo, Shunsuke, Chida, Masayuki, Yoshino, Ichiro, Suzuki, Hidemi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9367074/
https://www.ncbi.nlm.nih.gov/pubmed/35948946
http://dx.doi.org/10.1186/s12885-022-09973-8
_version_ 1784765708296519680
author Ito, Hiroyuki
Date, Hiroshi
Shintani, Yasushi
Miyaoka, Etsuo
Nakanishi, Ryoichi
Kadokura, Mitsutaka
Endo, Shunsuke
Chida, Masayuki
Yoshino, Ichiro
Suzuki, Hidemi
author_facet Ito, Hiroyuki
Date, Hiroshi
Shintani, Yasushi
Miyaoka, Etsuo
Nakanishi, Ryoichi
Kadokura, Mitsutaka
Endo, Shunsuke
Chida, Masayuki
Yoshino, Ichiro
Suzuki, Hidemi
author_sort Ito, Hiroyuki
collection PubMed
description OBJECTIVE: We studied the prognosis and clinicopathological background of lung adenocarcinoma predominance among patients who underwent lobectomy using data from the Japanese Joint Committee of Lung Cancer Registry. METHODS: Two thousand eight hundred sixty-three cases were extracted. Recurrence free survival (RFS) rates, overall survival (OS) rates and clinicopathological factors and epidermal growth factor receptor (EGFR) mutation status were examined. RESULTS: Median follow-up period was 65.5 months. Adenocarcinoma predominance was sub-grouped according to OS and RFS rate. In pathological stage I, 5-year RFS and OS rates were respectively 92.2% and 95.8% in group A (adenocarcinoma-in-situ + minimally invasive adenocarcinoma), 89.3% and 92.1% in group B (lepidic), 79.2% and 89.7% in group C (papillary + acinar + variants) and 69.0% and 79.0% in group D (solid + micropapillary). In pathological stage II + IIIA, they were, 43.6% and 72.4% in B, 39.5% and 66.9% in C and 31.0% and 53.7% in D. Group D showed significant worst outcome both in stage I and II + IIIA. Up stage rate from clinical stage I to pathological stage II + IIIA was 0.0%, 3.7%, 15.9% and 33.3%. The frequency of lymph-vessel, vascular, pleura invasion and positive EGFR mutation were 0.0%, 0.0%, 0.0% and 57.1% in group A, 15.6%, 10.0%, 12.1% and 55.1% in B, 36.6%, 31.8%, 29.7% and 44.9% in C, 50.2%, 57.8%, 38.9% and 21.3% in D. In group D, lymph-vessel, vascular and pleura invasion were most, EGFR mutation was least frequent not only in pathological stage I but also stage II + IIIA. In multivariate analysis, age, pathological stage, vascular invasion, and group D were independent factors affected RFS and OS. CONCLUSION: Limited to lobectomy cases, solid + micropapillary was independent prognostic factor both in early and locally advanced stage. Its malignant degree was related to the frequency of pathological invasive factors and EGFR mutation status.
format Online
Article
Text
id pubmed-9367074
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-93670742022-08-12 The prognostic impact of lung adenocarcinoma predominance classification relating to pathological factors in lobectomy, the Japanese Joint Committee of Lung Cancer Registry Database in 2010 Ito, Hiroyuki Date, Hiroshi Shintani, Yasushi Miyaoka, Etsuo Nakanishi, Ryoichi Kadokura, Mitsutaka Endo, Shunsuke Chida, Masayuki Yoshino, Ichiro Suzuki, Hidemi BMC Cancer Research OBJECTIVE: We studied the prognosis and clinicopathological background of lung adenocarcinoma predominance among patients who underwent lobectomy using data from the Japanese Joint Committee of Lung Cancer Registry. METHODS: Two thousand eight hundred sixty-three cases were extracted. Recurrence free survival (RFS) rates, overall survival (OS) rates and clinicopathological factors and epidermal growth factor receptor (EGFR) mutation status were examined. RESULTS: Median follow-up period was 65.5 months. Adenocarcinoma predominance was sub-grouped according to OS and RFS rate. In pathological stage I, 5-year RFS and OS rates were respectively 92.2% and 95.8% in group A (adenocarcinoma-in-situ + minimally invasive adenocarcinoma), 89.3% and 92.1% in group B (lepidic), 79.2% and 89.7% in group C (papillary + acinar + variants) and 69.0% and 79.0% in group D (solid + micropapillary). In pathological stage II + IIIA, they were, 43.6% and 72.4% in B, 39.5% and 66.9% in C and 31.0% and 53.7% in D. Group D showed significant worst outcome both in stage I and II + IIIA. Up stage rate from clinical stage I to pathological stage II + IIIA was 0.0%, 3.7%, 15.9% and 33.3%. The frequency of lymph-vessel, vascular, pleura invasion and positive EGFR mutation were 0.0%, 0.0%, 0.0% and 57.1% in group A, 15.6%, 10.0%, 12.1% and 55.1% in B, 36.6%, 31.8%, 29.7% and 44.9% in C, 50.2%, 57.8%, 38.9% and 21.3% in D. In group D, lymph-vessel, vascular and pleura invasion were most, EGFR mutation was least frequent not only in pathological stage I but also stage II + IIIA. In multivariate analysis, age, pathological stage, vascular invasion, and group D were independent factors affected RFS and OS. CONCLUSION: Limited to lobectomy cases, solid + micropapillary was independent prognostic factor both in early and locally advanced stage. Its malignant degree was related to the frequency of pathological invasive factors and EGFR mutation status. BioMed Central 2022-08-10 /pmc/articles/PMC9367074/ /pubmed/35948946 http://dx.doi.org/10.1186/s12885-022-09973-8 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Ito, Hiroyuki
Date, Hiroshi
Shintani, Yasushi
Miyaoka, Etsuo
Nakanishi, Ryoichi
Kadokura, Mitsutaka
Endo, Shunsuke
Chida, Masayuki
Yoshino, Ichiro
Suzuki, Hidemi
The prognostic impact of lung adenocarcinoma predominance classification relating to pathological factors in lobectomy, the Japanese Joint Committee of Lung Cancer Registry Database in 2010
title The prognostic impact of lung adenocarcinoma predominance classification relating to pathological factors in lobectomy, the Japanese Joint Committee of Lung Cancer Registry Database in 2010
title_full The prognostic impact of lung adenocarcinoma predominance classification relating to pathological factors in lobectomy, the Japanese Joint Committee of Lung Cancer Registry Database in 2010
title_fullStr The prognostic impact of lung adenocarcinoma predominance classification relating to pathological factors in lobectomy, the Japanese Joint Committee of Lung Cancer Registry Database in 2010
title_full_unstemmed The prognostic impact of lung adenocarcinoma predominance classification relating to pathological factors in lobectomy, the Japanese Joint Committee of Lung Cancer Registry Database in 2010
title_short The prognostic impact of lung adenocarcinoma predominance classification relating to pathological factors in lobectomy, the Japanese Joint Committee of Lung Cancer Registry Database in 2010
title_sort prognostic impact of lung adenocarcinoma predominance classification relating to pathological factors in lobectomy, the japanese joint committee of lung cancer registry database in 2010
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9367074/
https://www.ncbi.nlm.nih.gov/pubmed/35948946
http://dx.doi.org/10.1186/s12885-022-09973-8
work_keys_str_mv AT itohiroyuki theprognosticimpactoflungadenocarcinomapredominanceclassificationrelatingtopathologicalfactorsinlobectomythejapanesejointcommitteeoflungcancerregistrydatabasein2010
AT datehiroshi theprognosticimpactoflungadenocarcinomapredominanceclassificationrelatingtopathologicalfactorsinlobectomythejapanesejointcommitteeoflungcancerregistrydatabasein2010
AT shintaniyasushi theprognosticimpactoflungadenocarcinomapredominanceclassificationrelatingtopathologicalfactorsinlobectomythejapanesejointcommitteeoflungcancerregistrydatabasein2010
AT miyaokaetsuo theprognosticimpactoflungadenocarcinomapredominanceclassificationrelatingtopathologicalfactorsinlobectomythejapanesejointcommitteeoflungcancerregistrydatabasein2010
AT nakanishiryoichi theprognosticimpactoflungadenocarcinomapredominanceclassificationrelatingtopathologicalfactorsinlobectomythejapanesejointcommitteeoflungcancerregistrydatabasein2010
AT kadokuramitsutaka theprognosticimpactoflungadenocarcinomapredominanceclassificationrelatingtopathologicalfactorsinlobectomythejapanesejointcommitteeoflungcancerregistrydatabasein2010
AT endoshunsuke theprognosticimpactoflungadenocarcinomapredominanceclassificationrelatingtopathologicalfactorsinlobectomythejapanesejointcommitteeoflungcancerregistrydatabasein2010
AT chidamasayuki theprognosticimpactoflungadenocarcinomapredominanceclassificationrelatingtopathologicalfactorsinlobectomythejapanesejointcommitteeoflungcancerregistrydatabasein2010
AT yoshinoichiro theprognosticimpactoflungadenocarcinomapredominanceclassificationrelatingtopathologicalfactorsinlobectomythejapanesejointcommitteeoflungcancerregistrydatabasein2010
AT suzukihidemi theprognosticimpactoflungadenocarcinomapredominanceclassificationrelatingtopathologicalfactorsinlobectomythejapanesejointcommitteeoflungcancerregistrydatabasein2010
AT theprognosticimpactoflungadenocarcinomapredominanceclassificationrelatingtopathologicalfactorsinlobectomythejapanesejointcommitteeoflungcancerregistrydatabasein2010
AT itohiroyuki prognosticimpactoflungadenocarcinomapredominanceclassificationrelatingtopathologicalfactorsinlobectomythejapanesejointcommitteeoflungcancerregistrydatabasein2010
AT datehiroshi prognosticimpactoflungadenocarcinomapredominanceclassificationrelatingtopathologicalfactorsinlobectomythejapanesejointcommitteeoflungcancerregistrydatabasein2010
AT shintaniyasushi prognosticimpactoflungadenocarcinomapredominanceclassificationrelatingtopathologicalfactorsinlobectomythejapanesejointcommitteeoflungcancerregistrydatabasein2010
AT miyaokaetsuo prognosticimpactoflungadenocarcinomapredominanceclassificationrelatingtopathologicalfactorsinlobectomythejapanesejointcommitteeoflungcancerregistrydatabasein2010
AT nakanishiryoichi prognosticimpactoflungadenocarcinomapredominanceclassificationrelatingtopathologicalfactorsinlobectomythejapanesejointcommitteeoflungcancerregistrydatabasein2010
AT kadokuramitsutaka prognosticimpactoflungadenocarcinomapredominanceclassificationrelatingtopathologicalfactorsinlobectomythejapanesejointcommitteeoflungcancerregistrydatabasein2010
AT endoshunsuke prognosticimpactoflungadenocarcinomapredominanceclassificationrelatingtopathologicalfactorsinlobectomythejapanesejointcommitteeoflungcancerregistrydatabasein2010
AT chidamasayuki prognosticimpactoflungadenocarcinomapredominanceclassificationrelatingtopathologicalfactorsinlobectomythejapanesejointcommitteeoflungcancerregistrydatabasein2010
AT yoshinoichiro prognosticimpactoflungadenocarcinomapredominanceclassificationrelatingtopathologicalfactorsinlobectomythejapanesejointcommitteeoflungcancerregistrydatabasein2010
AT suzukihidemi prognosticimpactoflungadenocarcinomapredominanceclassificationrelatingtopathologicalfactorsinlobectomythejapanesejointcommitteeoflungcancerregistrydatabasein2010
AT prognosticimpactoflungadenocarcinomapredominanceclassificationrelatingtopathologicalfactorsinlobectomythejapanesejointcommitteeoflungcancerregistrydatabasein2010